| RTX |
Report |
Adjusted EPS |
BEAT |
pred ~$1.71 vs. cons $1.6686 |
MEDIUM |
| RTX |
Report |
Operating sales |
IN-LINE |
pred ~$23.05B vs. cons $22.9135B |
MEDIUM |
| RTX |
Report |
Raytheon operating sales |
IN-LINE |
pred ~$7.60B vs. cons $7.5436B |
MEDIUM |
| RTX |
Guide |
FY26 adjusted sales |
LOWER |
guide ~$93.0B midpoint vs. cons $94.226B |
MEDIUM |
| RTX |
Guide |
FY26 adjusted EPS |
LOWER |
guide ~$6.80 midpoint vs. cons $6.949 |
MEDIUM |
| RTX |
Guide |
FY26 FCF |
LOWER |
guide ~$8.50B midpoint vs. cons $8.596B |
MEDIUM |
| RTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| RTX |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implicit H2 reduction pressures revisions |
LOW |